Senescent cells in Giant Cell Arteritis have inflammatory phenotype participating in tissue injury via IL-6 dependent pathways

Objectives Age is the strongest risk factor of Giant Cell Arteritis (GCA), implying a possible pathogenetic role of cellular senescence. To address this question, we applied an established senescence specific multi-marker algorithm in tissue artery biopsies (TABs) of GCA patients. Methods Seventy five positive TABs from GCA patients and 22 negative from patients with Polymyalgia Rheumatica (PMR) were retrospectively retrieved and analyzed. Senescent cells and their histologic origin were identified with specific cellular markers; IL-6 and MMP-9 were investigated as components of the senescent associated secretory phenotype (SASP) by triple co-staining. GCA or PMR artery culture supernatants were applied to primary skin fibroblasts with or without IL-6 blocking agent to explore the induction of IL-6 associated cellular senescence. Results Senescent cells were mainly present in GCA arteries at higher proportion compared to PMR (9.50% vs 2.66% respectively, p<0.0001) and were mainly originated from fibroblasts, macrophages and endothelial cells. IL-6 was expressed by senescent fibroblasts and macrophages while MMP-9 by fibroblasts only. IL-6 positive senescent cells were associated with the extension of vascular inflammation (adventitial limited disease vs transmural inflammation: 10.02% vs 4.37% respectively, p<0.0001). GCA but not PMR artery culture supernatant could induce IL-6-associated senescence that was partially inhibited by IL-6 blockade. Conclusions Senescent cells with inflammatory phenotype are present in GCA arteries and are associated with the tissue inflammatory bulk. These findings might suggest a potential implication in disease pathogenesis by perpetuating inflammation and affecting vascular remodeling via IL-6 dependent mechanisms.

[1]  E. Brouwer,et al.  Indication of Activated Senescence Pathways in the Temporal Arteries of Patients With Giant Cell Arteritis , 2023, Arthritis & rheumatology.

[2]  Soyoung Lee,et al.  COVID-19 and cellular senescence , 2022, Nature Reviews Immunology.

[3]  I. Wicks,et al.  Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2022, Annals of the Rheumatic Diseases.

[4]  C. Dani,et al.  Senescent macrophages in the human adipose tissue as a source of inflammaging , 2022, GeroScience.

[5]  F. Buettner,et al.  Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. , 2022, Cancer cell.

[6]  B. Stripp,et al.  Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis , 2022, European Respiratory Journal.

[7]  A. Aboussekhra,et al.  Tocilizumab suppresses the pro-carcinogenic effects of breast cancer- associated fibroblasts through inhibition of the STAT3/AUF1 pathway. , 2021, Carcinogenesis.

[8]  J. Stone,et al.  New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension , 2021, Rheumatology.

[9]  Daniele Di Mauro,et al.  New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine? , 2021, The Lancet. Rheumatology.

[10]  A. Lazaris,et al.  Neutrophil extracellular traps in giant cell arteritis biopsies: presentation, localization and co-expression with inflammatory cytokines. , 2021, Rheumatology.

[11]  J. Campisi,et al.  Algorithmic assessment of cellular senescence in experimental and clinical specimens , 2021, Nature Protocols.

[12]  J. Gil,et al.  Senescence and the SASP: many therapeutic avenues , 2020, Genes & development.

[13]  C. Schmitt,et al.  Cellular Senescence: Defining a Path Forward , 2019, Cell.

[14]  V. Gorgoulis,et al.  Senescence and senotherapeutics: a new field in cancer therapy , 2019, Pharmacology & therapeutics.

[15]  L. Tian,et al.  MMP (Matrix Metalloprotease)-9–Producing Monocytes Enable T Cells to Invade the Vessel Wall and Cause Vasculitis , 2018, Circulation research.

[16]  C. Kallenberg,et al.  Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis? , 2018, Arthritis & rheumatology.

[17]  S. Melov,et al.  Unmasking Transcriptional Heterogeneity in Senescent Cells , 2017, Current Biology.

[18]  A. Rizzo,et al.  New insights into the pathogenesis of giant cell arteritis. , 2017, Autoimmunity reviews.

[19]  C. Wijmenga,et al.  A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. , 2017, American journal of human genetics.

[20]  Sagar,et al.  DNA Damage Signaling Instructs Polyploid Macrophage Fate in Granulomas , 2016, Cell.

[21]  C. Conover,et al.  Senescent intimal foam cells are deleterious at all stages of atherosclerosis , 2016, Science.

[22]  N. Karamanos,et al.  Ionizing radiation-mediated premature senescence and paracrine interactions with cancer cells enhance the expression of syndecan 1 in human breast stromal fibroblasts: the role of TGF-β , 2016, Aging.

[23]  Ansar Karimian,et al.  Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. , 2016, DNA repair.

[24]  L. Cimino,et al.  MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis , 2015, Annals of the rheumatic diseases.

[25]  C. Weyand,et al.  Immune mechanisms in medium and large-vessel vasculitis , 2013, Nature Reviews Rheumatology.

[26]  P. Barnes,et al.  Dysfunction of Endothelial Progenitor Cells from Smokers and Chronic Obstructive Pulmonary Disease Patients Due to Increased DNA Damage and Senescence , 2013, Stem cells.

[27]  C. Franceschi,et al.  MicroRNAs linking inflamm-aging, cellular senescence and cancer , 2013, Ageing Research Reviews.

[28]  A. Iagnocco,et al.  2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative , 2012, Annals of the rheumatic diseases.

[29]  Y. J. Liao,et al.  Giant cell arteritis: immune and vascular aging as disease risk factors , 2011, Arthritis research & therapy.

[30]  J. Campisi,et al.  The senescence-associated secretory phenotype: the dark side of tumor suppression. , 2010, Annual review of pathology.

[31]  Javier Martín,et al.  Epidemiology of giant cell arteritis and polymyalgia rheumatica. , 2009, Arthritis and rheumatism.

[32]  J. Nolla,et al.  Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. , 2007, Seminars in arthritis and rheumatism.

[33]  C. Nordborg,et al.  Early menopause, low body mass index, and smoking are independent risk factors for developing giant cell arteritis , 2005, Annals of the rheumatic diseases.

[34]  D. Colomer,et al.  Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. , 2003, Rheumatology.

[35]  A. Papavassiliou,et al.  p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner. , 2003, The EMBO journal.

[36]  G. Hannon,et al.  Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.